Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
12 déc. 2022 10h00 HE
|
Affimed N.V.
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid...
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
10 déc. 2022 15h00 HE
|
Affimed N.V.
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13...
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
10 déc. 2022 14h20 HE
|
Affimed N.V.
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had...
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
01 déc. 2022 16h05 HE
|
Affimed N.V.
Review of clinical data and development plans for AFM13 in hematologic malignanciesLive event and webcast on Saturday, December 10 at 4:00 p.m. CST HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE...
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
15 nov. 2022 06h30 HE
|
Affimed N.V.
AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a...
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
07 nov. 2022 08h05 HE
|
Affimed N.V.
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a...
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
04 nov. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
03 nov. 2022 09h15 HE
|
Affimed N.V.
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimed’s AFM13 in combination with cord blood-derived NK cells demonstrated...
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
03 nov. 2022 09h05 HE
|
Affimed N.V.
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an...
Affimed to Present at the 2022 Jefferies London Healthcare Conference
01 nov. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...